You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TGR-1202

Showing 1 - 25 of 50
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myelofibrosis, Polycythemia Vera Trial in United States (TGR-1202, ruxolitinib)

Active, not recruiting
  • Myelofibrosis
  • Polycythemia Vera
  • Phoenix, Arizona
  • +4 more
Jun 20, 2022

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in United States (TGR-1202, TGR-1202 + Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • TGR-1202
  • TGR-1202 + Ublituximab
  • Huntsville, Alabama
  • +16 more
Jul 20, 2022

Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)

Completed
  • Waldenstrom Macroglobulinemia
  • Washington, District of Columbia
  • +3 more
Oct 19, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)

Terminated
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
Jul 20, 2022

Follicular Lymphoma Trial in New York (TGR-1202)

Terminated
Has Results
  • Follicular Lymphoma
  • TGR-1202
  • New York, New York
    Columbia University Medical Center
Jun 28, 2021

Hodgkin Disease, Lymphoma, Non-hodgkin Trial in New York (Carfilzomib, TGR-1202)

Terminated
Has Results
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
Jun 28, 2021

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL Trial in New York (Umbralisib, Ublituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
Mar 29, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Chronic Lymphocytic Leukemia Trial in Worldwide (Obinutuzumab, Ublituximab, TGR-1202)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Obinutuzumab
  • +3 more
  • Huntsville, Alabama
  • +153 more
Aug 19, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Omaha (Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202)

Completed
Has Results
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Omaha, Nebraska
    University of Nebraska Medical Center
Feb 12, 2020

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma Trial in United States (Ublituximab + TGR-1202, Ublituximab + TGR-1202 +

Completed
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
  • Ublituximab + TGR-1202
  • +2 more
  • Huntsville, Alabama
  • +5 more
Nov 4, 2019

Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1 Trial in Boston (Umbralisib, Rituximab)

Recruiting
  • Lymphoma
  • +6 more
  • Boston, Massachusetts
  • +1 more
Aug 31, 2020

Chronic Lymphocytic Leukemia Trial in Huntsville, Memphis (TGR-1202 + Obinutuzumab + Chlorambucil)

Completed
  • Chronic Lymphocytic Leukemia
  • TGR-1202 + Obinutuzumab + Chlorambucil
  • Huntsville, Alabama
  • +1 more
Oct 1, 2019

Hodgkin's Lymphoma Trial in United States (TGR-1202 + brentuximab vedotin)

Completed
  • Hodgkin's Lymphoma
  • TGR-1202 + brentuximab vedotin
  • Duarte, California
  • +3 more
Oct 1, 2019

Pancreatic Cancer, Colorectal Cancer, Rectal Cancer Trial in Nashville (TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin +

Completed
  • Pancreatic Cancer
  • +5 more
  • TGR-1202
  • +3 more
  • Nashville, Tennessee
    TG Therapeutics Trial Site
Oct 1, 2019

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
Jan 20, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022